ENT & Plastic Surgery Associates: A Blueprint for Success in ENT Practices
Since 1956, ENT & Plastic Surgery Associates (ENTPSA) has been a trusted provider of exceptional comprehensive head and neck care in and around Orlando, Florida. With over 30 providers across six locations, they offer a wide range of services, from facial plastic surgery and hearing device solutions to allergy and voice care. Their partnership with Brevium highlights a continued commitment to refining processes, closing patient care gaps, and exceeding individual patient expectations through state-of-the-art innovation.
Identifying Opportunities with Brevium
ENT & Plastic Surgery Associates was introduced to Brevium in early 2023, leveraging the technology’s proven success in other specialties to address their practice’s growth challenges. Brevium’s initial connection identified over 10,000 patients lost to follow up, while the Brevium Stitch uncovered an additional 29,000 overdue patients from legacy PM data following the practice’s 2021 transition to ModMed. Seeking to recover these patients and prevent further attrition, newly hired CEO Jeremy Jones recognized the need to address their “leaky faucet” by improving internal operations before fully ramping up Brevium’s capabilities—ensuring long-term efficiency and retention.
With a strategic, phased implementation approach, ENTPSA prioritized operational readiness to prevent provider overload and ensure sustainable growth. Weekly meetings with Jones, Medical Director Jeff Lehman and Brevium’s team ensured they targeted the highest priority patients using relevant diagnostic codes and tailored messaging. Initial outreach focused on chronic conditions like allergic rhinitis and chronic sinusitis, gradually scaling Brevium to full capacity to meet critical patient needs while driving measurable value.
Leveraging Brevium for Long-Term Success
Since its launch in July 2023, Brevium has delivered significant returns by helping ENTPSA reconnect with their overdue patients. Following a three-month testing and ramp-up phase, weekly appointments increased from 60 to an average of 290 through Brevium alone—a figure that has remained consistent over time. To date, 14,872 patients have been successfully reactivated and returned to the clinic for care. Medical Director Jeff Lehman highlights Brevium’s dual impact: effectively re-engaging high-risk patients for critical treatment and monitoring while seamlessly optimizing appointment volume and provider schedules. With ENTPSA recently acquiring two new allergy practices, they intend to replicate this proven approach, leveraging Brevium as a scalable resource for sustainable expansion and continued success.
“Brevium has been instrumental in re-engaging our high-risk patients who need monitoring and management of their critical medical conditions. It seamlessly fills our provider schedules while ensuring that patients receive the treatments they need. This dual impact of improving patient outcomes and optimizing operations has been a game-changer for our practice.” —Jeff Lehman, Medical Director
“We knew we had to address our ‘leaky faucet’ problem, and Brevium provided the perfect solution. By strategically implementing their technology, we’ve not only recovered thousands of lost-to-follow-up patients but also ensured sustainable. Brevium is a key part of our long-term strategy for success.”—Jeremey Jones, CEO
“Brevium’s phased approach and tailored outreach were exactly what we needed to tackle our growth challenges. From identifying priority patients to increasing weekly appointments significantly, Brevium has exceeded our expectations in driving measurable value and supporting our expansion goals.”—Cole Sillaman, Director of Operations
